Globenewswire·2026-02-26 23:36PayPal Holdings, Inc. (NASDAQ:PYPL) - The class action lawsuit alleges that PayPal misled investors regarding its revenue outlook and growth potential during the class period from February 25, 2025, to February 2, 2026 [6] - PayPal's fourth quarter and full fiscal year 2025 results, announced on February 3, 2026, revealed disappointing earnings and a withdrawal of its 2027 financial targets, leading to a stock price drop of over 20% [6] - The lawsuit claims that the company's optimistic growth plans were unrealistic and that the management failed to provide clear direction, contributing to operational issues [6] REGENXBIO Inc. (NASDAQ:RGNX) - The class action lawsuit involves allegations that REGENXBIO provided misleading information about its gene therapy product candidate RGX-111 during the class period from February 9, 2022, to January 27, 2026 [6] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a 17.8% decline in stock price from $13.41 to $11.01 in one day [6] - The lawsuit claims that the company made overly positive assertions about RGX-111's trial success while concealing material adverse facts regarding its efficacy and safety [6]